Jeff Garro
Stock Analyst at Stephens & Co.
(0.58)
# 3,527
Out of 4,667 analysts
40
Total ratings
16.67%
Success rate
-18.9%
Average return
Main Sectors:
Stocks Rated by Jeff Garro
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| SLP Simulations Plus | Initiates: Overweight | $39 | $27.62 | +41.20% | 1 | Nov 15, 2024 | |
| HCAT Health Catalyst | Maintains: Equal-Weight | $7 → $9 | $7.54 | +19.36% | 2 | Nov 14, 2024 | |
| EVH Evolent Health | Downgrades: Equal-Weight | $16 | $11.95 | +33.89% | 4 | Nov 8, 2024 | |
| ACCD Accolade | Maintains: Overweight | $10 → $8 | $3.49 | +129.23% | 6 | Oct 9, 2024 | |
| PHR Phreesia | Reiterates: Overweight | $28 | $18.55 | +50.94% | 8 | May 31, 2024 | |
| CERT Certara | Reiterates: Overweight | $20 | $9.88 | +102.43% | 4 | Oct 11, 2023 | |
| TDOC Teladoc Health | Reiterates: Equal-Weight | $28 | $8.93 | +213.55% | 2 | Jul 26, 2023 | |
| RCM R1 RCM | Initiates: Overweight | $18 | $14.31 | +25.79% | 1 | Apr 12, 2023 | |
| PRVA Privia Health Group | Initiates: Overweight | $33 | $21.11 | +56.32% | 1 | Apr 12, 2023 | |
| OPRX OptimizeRx | Maintains: Neutral | $29 → $16 | $4.08 | +292.16% | 2 | Aug 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $15 → $20 | $11.09 | +80.34% | 3 | Aug 5, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $5 → $3.9 | $4.78 | -18.41% | 2 | May 11, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $4 → $3 | $2.52 | +19.05% | 3 | May 6, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $231 → $255 | $191.33 | +33.28% | 1 | Apr 29, 2022 |
Simulations Plus
Nov 15, 2024
Initiates: Overweight
Price Target: $39
Current: $27.62
Upside: +41.20%
Health Catalyst
Nov 14, 2024
Maintains: Equal-Weight
Price Target: $7 → $9
Current: $7.54
Upside: +19.36%
Evolent Health
Nov 8, 2024
Downgrades: Equal-Weight
Price Target: $16
Current: $11.95
Upside: +33.89%
Accolade
Oct 9, 2024
Maintains: Overweight
Price Target: $10 → $8
Current: $3.49
Upside: +129.23%
Phreesia
May 31, 2024
Reiterates: Overweight
Price Target: $28
Current: $18.55
Upside: +50.94%
Certara
Oct 11, 2023
Reiterates: Overweight
Price Target: $20
Current: $9.88
Upside: +102.43%
Teladoc Health
Jul 26, 2023
Reiterates: Equal-Weight
Price Target: $28
Current: $8.93
Upside: +213.55%
R1 RCM
Apr 12, 2023
Initiates: Overweight
Price Target: $18
Current: $14.31
Upside: +25.79%
Privia Health Group
Apr 12, 2023
Initiates: Overweight
Price Target: $33
Current: $21.11
Upside: +56.32%
OptimizeRx
Aug 10, 2022
Maintains: Neutral
Price Target: $29 → $16
Current: $4.08
Upside: +292.16%
Aug 5, 2022
Maintains: Overweight
Price Target: $15 → $20
Current: $11.09
Upside: +80.34%
May 11, 2022
Maintains: Underweight
Price Target: $5 → $3.9
Current: $4.78
Upside: -18.41%
May 6, 2022
Maintains: Neutral
Price Target: $4 → $3
Current: $2.52
Upside: +19.05%
Apr 29, 2022
Upgrades: Overweight
Price Target: $231 → $255
Current: $191.33
Upside: +33.28%